Our Take
Three companies captured nearly all attention in May's biotech fundraising, but the real story is non-dilutive capital (Apogee's $1.3B royalty deal) starting to rival equity rounds as a way to fund late-stage trials.
Why it matters
Biotech companies are running out of traditional venture money for phase 3 trials, and Wall Street is filling the gap with structured debt products. If this trend accelerates, it changes who controls clinical programs and how risk is priced.
Do this week
Finance leads: audit your company's debt capacity and royalty runway through phase 3 completion before Q3 earnings calls so you can model non-dilutive alternatives to equity raises.
Three megadeals dominated May biotech fundraising
Isomorphic Labs, the U.K. company behind AlphaFold3, closed a $2.1 billion series B round (company-reported). The funding will accelerate its IsoDDE AI drug design engine and clinical pipeline expansion.
Apogee Therapeutics secured $1.3 billion in non-dilutive capital from Blackstone Life Sciences, structured as up to $800 million in synthetic royalty and up to $500 million in senior debt. Apogee will use the proceeds to advance zumilokibart, its lead atopic dermatitis candidate, through phase 3 trials.
CellCentric raised $220 million in series D funding to advance inobrodib through pivotal clinical studies and initiate a global phase 3 trial in the second half of 2026.
In public markets, Avalo Therapeutics priced a $375 million offering for its abdakibart program, Editas Medicine announced a $319.4 million public offering, and Odyssey Therapeutics raised $304 million in an IPO and concurrent private placement (all company-reported).
Non-dilutive financing is reshaping how late-stage programs get funded
Private biotech fundraising totaled $4.265 billion in May, the bulk driven by Isomorphic and Apogee. Public offerings added $1.298 billion across four rounds. But the composition matters more than the total: Apogee's deal is a signal that royalty-backed debt structures are now competitive with equity for funding phase 3 trials.
Traditional venture capital faces denominator constraints and portfolio concentration risk at scale. Structured finance products, by contrast, allow sponsors like Blackstone to purchase cash flow rights without taking voting control. For biotech CFOs, this means phase 3 acceleration no longer requires dilution or massive equity raises.
The catch: royalty deals strip upside and tie cash flow to regulatory approvals. If a program fails, the debt still comes due. Equity investors take the hit; royalty buyers get paid first. This inverts risk hierarchy and makes company balance sheets riskier for equity holders downstream.
Track non-dilutive deal terms and structures
Practitioners in biotech strategy should catalog the terms of Apogee's deal and similar structures as they emerge. Blackstone's willingness to deploy $1.3 billion on a single program signals institutional capital is flowing into late-stage biotech but on terms that require operational discipline and clear regulatory timelines. If your company is in phase 2 with an 18+ month runway to phase 3, model both equity and royalty scenarios now so you can negotiate from strength, not desperation, in 12 months.